High Level of Rheumatoid Factor is Associated with Hepatitis B Viremia in Patients with Chronic Hepatitis B by ARAI Jun et al.
Showa Univ J Med Sci 26（1）, 75～83, March 2014
High Level of Rheumatoid Factor is Associated with Hepatitis B 
Viremia in Patients with Chronic Hepatitis B
Jun ARAI, Takayoshi ITO, Miyuki MIYASHITA,  
Yuu SHIMODUMA, Manabu UCHIKOSHI, Kenichi MORIKAWA,  
Junichi EGUCHI, Eiichi HAYASHI, Hisako NOZAWA  
and Hitoshi YOSHIDA
Abstract : Hepatitis viruses are causative agents for chronic hepatitis, liver cirrhosis 
and hepatocellular carcinoma.  However these viruses are also associated with 
lymphoproliferative disorders （LPDs）, such as essential mixed cryoglobulinemia 
and B-cell non-Hodgkin’s lymphoma.  Indeed, hepatitis C virus infection has been 
confirmed to be associated with LPDs, but the pathogenic mechanism remains 
unclear.  In this study, we investigated the relationship between hepatitis B virus 
（HBV） infection and LPDs in 84 patients with chronic hepatitis B （CH-B）.  LPD 
markers, such as cryoglobulinemia, high levels of rheumatoid factor （RF）, hypo-
complementemia, and B cell clonality, were measured and analyzed along with viral 
factors.  Results showed that high levels of RF were observed in 39.5％ of patients 
with CH-B.  These high RF levels were not associated with abnormal levels of 
other LPD markers, but only with the presence of HBV DNA in the sera of 
these patients.  Undergoing therapy with nucleotide analogues was also associated 
with high RF.  In two patients with CH-B, decreasing levels of RF were observed 
during antiviral therapy.  In conclusion, high RF levels are associated with HBV 
viremia in patients with CH-B.  HBV infection also plays an important role in the 
genesis of LPDs in patients with viral hepatitis..
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Introduction
　Infection with hepatitis viruses causes a variety of extra hepatic manifestations, such as 
cryoglobulinemia, malignant lymphoma, and glomerulonephritis.  In particular, lymphoproliferative 
disorders （LPDs） and autoimmune diseases are common abnormalities among patients infected 
with hepatitis virus1）.  The prevalence of hepatitis C virus （HCV） and hepatitis B virus （HBV） 
carrier status has been reported to be 10.1％ and 7.3％, respectively, in patients with non-
Hodgkin’s lymphoma2）.  These rates are around five-fold higher than that of the general Japanese 
population.  Furthermore, these abnormalities are observed not only in patients with active 
hepatitis but also asymptomatic patients, suggesting that regular examination is necessary for the 
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identification of immunologic disorders especially in patients with asymptomatic viral hepatitis.  
　We previously reported a high prevalence of abnormalities in LPD markers are found in 
patients with chronic hepatitis C （CH-C）3）.  These abnormalities are associated with HCV 
infection and/or adsorption with B cells of the patients.  Cryoglobulinemia, high levels of 
rheumatoid factor （RF）, low complement levels and clonal expansion of B cells are frequently 
observed in patients with CH-C.  About 74％ of the patients in our previous study were HCV 
RNA-positive in B cells isolated from the patients studied.  These results suggest that HCV 
infection plays an important role not only in liver disease but also in immunological disorders. 
In fact, a recent study also demonstrated that abnormal activation of B cells was observed in 
patients with both chronic hepatitis B （CH-B） and C 4）.  Therefore in this study, we investigated 
LPD markers in CH-B patients to determine whether HBV infection also induces LPDs and/or 
immunologic disorders in patients with CH-B.
Patients and Methods
Patients
　From 2002 through 2013, 84 patients with CH-B, who were managed at Showa University 
Hospital, were enrolled in this retrospective study.  Twenty of these patients underwent antiviral 
therapy using nucleic acid analogues.  Diagnosis of HBV infection was based on the detection 
of hepatitis B surface antigen and HBV DNA in the serum prior to the initiation of therapy. 
Viral information （HBV genotype and serum HBV DNA titer）, host factors （age, gender, platelet 
count, serum alanine transaminase ［ALT］ and γ-glutamyltranspeptidase ［γ-GTP］）, immunological 
markers （immunoglobulin ［Ig］ G, IgA and IgM） and markers for LPDs （cryoglobulinemia, high 
levels of RF, hypocomplementemia, and B cell clonality） were measured and analyzed.
　The study protocol was approved by the Ethics Committee of Showa University School of 
Medicine, Tokyo, Japan.  Informed written consent was obtained from each participant and the 
study followed the ethical guidelines of the 1975 Declaration of Helsinki.  
LPD markers
　Cryoglobulinemia was detected by a semi-quantitative centrifugation method.  Briefly, blood 
samples were centrifuged at 600 xg for 20 min at 37℃.  Sera were cooled to 4℃ and left to 
stand for 48 h, and centrifuged again at 2,500 xg for 10 min at 4℃.  The emergence of cryocrit 
at 4℃ and its disappearance by warming up to 37℃ for 20 min was regarded as positive for 
cryoglobulin.  RF was determined by the latex turbidimetric assay.  Complement component 3 
（C3） and 4 activity was determined by immune nephelometry, while total hemolytic complement 
was assayed by the immunoturbidimetric method.
Amplification of Ig-VH region by polymerase chain reaction and B cell clonality assay
　In 63 patients with CH-B, clonal expansion of B cells （B cell clonality） was determined from 
the sequence uniformity of the complementarity-determining region 3 of the immunoglobulin 
heavy chain （Ig-VH ; Fig. 1A）5）.  RNA （1µl） from peripheral blood mononuclear cells derived 
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from the patients with CH-B was reverse transcribed into cDNA and amplified using the 
GeneAmpⓇ EZ rTth RNA polymerase chain reaction kit （Applied Biosystems, Inc., Foster City, 
CA）, according to the manufacturer’s instructions.  Amplification was carried out with the FW3 
primer （5’-CTG AGG ACA CGG CCG TGT ATT ACT G-3’） in the VH region and the hM3 
primer （5’-GGA AAA GGG TTG GGG CGG AT-3’） located 8 nt downstream from the start 
of the CH1 exon.  The polymerase chain reaction products were visualized by staining with 
ethidium bromide after they had been electrophoresed on 4％ agarose gels.  A single band on 
the agarose gel indicates the presence of clonal expansion of B cells in the patient （Fig. 1B）, 
while a broad band indicates the absence of clonality.  
Statistical Analysis
　The medians of continuous variables, not normally distributed, were compared by the Mann-
Whitney U test.  Comparison of discontinuous variables was performed by the chi-square test or 
Fisher’s exact test using JMP software （version 10, SAS Institute, Cary, NC）.  A P-value＜0.05 
was considered significant.  Values with a normal distribution were expressed as mean±SE.  Data 
from variables that were not normally distributed were transformed into log values as required.  
Results
High levels of RF were observed in patients with CH-B 
　The clinical characteristics of patients with CH-B are shown in Table 1.  High levels of RF were 
Fig. 1.  （A） Scheme of primers used for the B cell clonality assay. The FW3 
and hM3 primers were used for amplification of the complementarity-
determining region 3 （CDR3） gene. （B） The broad bands, with 
molecular sizes around 300 to 330 base pairs, are negative （lanes 1 to 
3）, while the single band, indicated by the arrow, is positive （lane 4） 
for monoclonality in the CDR3 gene, in which molecular size should 
vary in each B cell of a healthy adult.
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observed in patients with CH-B, with 39.5％ of patients having high RF （≥10 IU/mL ; Table 1）. 
Low C3 was also observed in 10.3％ of patients, while B cell clonality was only identified in one 
patient （1.6％） with CH-B.  Our results show that 50.0％ of these patients with CH-B have at least 
one abnormal LPD marker.
Abnormal RF was not associated with any other LPD markers but with the presence of HBV 
DNA in sera
　We tried to determine if any parameters were associated with abnormal levels of RF in 
patients with CH-B.  Table 2 shows that no parameter was identified among the biochemical, 
Table 1.    Clinical characteristics of patients with chronic 
hepatitis B （CH-B）
CH-B patients （n＝84）
Age （years） 47.8±13.0
Gender （male/female） 45/39
Platelets （104/ µL） 20.5±5.0
ALT （IU/L） 49.8±79.0
γGTP （IU/L） 28.2±2.3
IgG （mg/dL） 1276.8±266.4
IgA （mg/dL） 227.0±107.7
IgM （mg/dL） 118.0±84.4
Cryoglobulinemia 3/80 （3.7％）
RF （≥ 10 IU/mL） 32/81 （39.5％）
C3 （＜86 mg/dL） 8/78 （10.3％）
C4 （＜10 mg/dL） 1/78 （1.3％）
CH50 （＜20 U/mL） 0/78 （0.0％）
B cell clonality 1/63 （1.6％）
HBV DNA （log copies/mL） 2.39±0.32
HBs antigen （＞ 200 IU/mL） 61/81 （75.3％）
HBe antibody-positive 63/69 （91.3％）
HBV genotype （A/B/C/D/ND） 6/17/32/1/38
Values are mean±SE or n （％）.
Abbreviations : ALT, alanine transaminase ; γGTP, γ-gluta-
myl trans peptidase ; RF, rheumatoid factor ; C3, complement 
component 3 ; C4, complement component 4 ; CH50, total 
hemolytic complement ; HBV, hepatitis B virus ; HBs, hepatitis 
B surface ; ND, not done.
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immunologic and LPD markers.  However, when we examined viral markers, we found the HBV 
DNA titers in patients whose RF was more than 10 IU/mL were significantly higher than those 
in patients whose RF was less than 10 IU/mL （P＝0.005 ; Table 3）.  We also investigated the 
effect of antiviral therapy using a nucleotide analogue against abnormal levels of RF.  Table 3 
shows that in the CH-B patients receiving antiviral therapy, a significantly higher proportion of 
patients had normal RF levels （＜10 IU/mL） than high RF levels （≥ 10 IU/mL ; P＝0.002）.
Relationship between HBV DNA titers and levels of RF in sera of CH-B patients
　We next investigated the relationship between HBV DNA titers and levels of RF.  Table 
4 shows that in CH-B patients with HBV DNA titers of more than 5.0 log copies/mL, the 
proportion of patients with high levels of RF （≥ 10 IU/mL） was similar to those patients with 
normal levels of RF （＜10 IU/mL）.  On the other hand, in CH-B patients with HBV DNA 
titers less than 3.0 log copies/mL, the proportion of patients with high levels of RF （≥ 10 IU/
mL） was significantly lower than those with normal RF levels （＜10 IU/mL ; P＜0.001）.
Table 2.    Comparison of LPD markers between patients with and without an 
abnormally high RF level
RF＜10 IU/mL
（n＝49）
RF ≥ 10 IU/mL
（n＝32）
P-value
Age （years） 49.5±1.9 45.9±2.3 ns
Gender （male/female） 26/23 17/15 ns
ALT （IU/L） 48.9±11.1 48.7±13.7 ns
Platelets （104/ µL） 20.2±0.7 20.7±0.9 ns
γGTP （IU/L） 30.1±3.0 26.4±3.9 ns
IgG 1238.6±49.2 1344.7±63.6 ns
IgA 227.1±19.9 236.7±25.7 ns
IgM 117.1±15.7 120.1±20.3 ns
Cryoglobulinemia 3/49 （6.1％） 0/31 （0.0％） ns
C3 （＜86 mg/dL） 6/48 （12.5％） 1/28 （3.6％） ns
C4 （＜10 mg/dL） 0/48 （0.0％） 1/28 （3.6％） ns
CH50 （＜20 U/mL） 0/48 （0.0％） 0/28 （0.0％） ns
Values are mean±SE or n （％）.
Abbreviations : LPD, lymphoproliferative disorder ; RF, rheumatoid factor ; ALT, 
alanine transaminase ; γGTP, γ-glutamyltranspeptidase ; C3, complement component 
3 ; C4, complement component 4 ; CH50, total hemolytic complement ; ns, not 
significant.
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Time course of HBV DNA titers and levels of RF in sera of patients during nucleotide analogue 
therapy
　We further investigated the effects of antiviral therapy on RF levels in two patients with 
CH-B （Fig. 2）.  The two patients （Cases 1 and 2） were treated daily with 0.5 mg of entecavir 
and HBV DNA titers and RF levels were monitored throughout the therapy.  Case 1 is a 
20-year-old man who was HBe antigen-positive, while Case 2 is a 70-year-old man who was 
HBe antigen-negative.  Figure 2 shows that the level of RF was 33.3 IU/mL and the HBV DNA 
titer was 5.9 log copies/mL in Case 1 before therapy.  When the HBV DNA titers became 
undetectable 7 months after the beginning of therapy, the level of RF had dropped to less than 
7 IU/mL.  In Case 2, the RF level was 45.4 IU/mL and the HBV DNA titer was 4.6 log copies/
mL before therapy.  When the HBV DNA titers became undetectable 40 months after the 
beginning of therapy, the RF level was reduced to 7 IU/mL.  These results confirm that a high 
level of RF factor is associated with viremia of HBV in patients with CH-B.
Table 3.    Comparison of HBV markers between patients with and without an 
abnormally high RF level
RF＜10 IU/mL　（n
＝49）
RF ≥ 10 IU/mL　（n
＝32）
P-value
HBV DNA（log copies/
mL）
3.31±0.29 4.66±0.35 0.005＊
HBs antigen（＞ 200 IU/
mL）
33/47 （70.2％） 25/31 （80.7％） ns
HBe antibody-positive 39/42 （92.9％） 23/25 （92.0％） ns
HBV genotype （A/B/C/D） 3/11/21/0 3/6/9/1 ns
Under treatment with 
nucleotide analogue
18/49 （36.7％） 2/32 （6.3％） 0.002＊
Values are mean±SE or n （％）. ＊Significant difference between the two groups （P
＜0.01） by Fisher’s exact analysis.
Abbreviations : HBV, hepatitis B virus ; RF, rheumatoid factor ; HBs, hepatitis B 
surface ; ns, not significant.
Table 4.    Relationship between HBV DNA titer and abnormal RF level
RF＜10 IU/mL
（n＝49）
RF ≥ 10 IU/mL
（n＝32）
P-value
HBV DNA＜3.0（log copies/mL） 28/49 （57.1％） 5/32 （15.6％） ＜0.001
HBV DNA ≥ 5.0（log copies/mL） 11/49 （22.5％） 9/32 （28.1％） ns
Values are n （％）. ＊Significant difference between the two groups （P＜0.01） by Fisher’s 
exact analysis.
Abbreviations : HBV, hepatitis B virus ; RF, rheumatoid factor ; ns, not significant.
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Discussion
　It has been epidemiologically demonstrated that hepatitis viruses, especially HCV, cause 
a number of extrahepatic manifestations6，7）.  Among these manifestations, LPDs are most 
closely related to HCV infection8）.  Hence, it has been widely accepted that chronic infection 
Fig. 2.  Time course for hepatitis B virus （HBV） DNA titers and rheumatoid 
factor （RF） levels in two patients with chronic hepatitis B, Case 1 （A） 
and Case 2 （B）, after the beginning of antiviral therapy using entecavir 
（ETV）.
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with HCV leads to a clonal expansion of B cells and that the sustained proliferation of 
B cells can promote the occurrence of genetic mutations8）.  HBV also causes a variety of 
extrahepatic manifestations.  The joints, muscle, and skin are the main locations of these 
clinical manifestations.  Autoimmune diseases and LPDs, such as malignant lymphoma and 
mixed cryoglobulinemia, are also common disorders9）.  Furthermore, asymptomatic disorders of 
immunologic and LPD markers have been observed in patients with CH-B, as well as in patients 
with CH-C.  In one study, 15％ of CH-B patients had at least one immunologic abnormality, 
mainly anti-smooth muscle antibodies and anti-nuclear antibodies10）.  Most of these abnormalities 
are associated with disorders of B cells.
　The present study has revealed that high levels of RF and low C3 levels are major 
abnormalities among patients with CH-B.  In particular, high levels of RF were observed in 
39.5％ of patients with CH-B.  RF is the antibody against the Fc portion of IgG.  High levels 
of RF are frequently observed not only in patients with rheumatic diseases, but also with non-
rheumatic diseases, including mixed cryoglobulinemia, Sjögren’s syndrome, mixed connective tissue 
disease, and even in healthy subjects11）.  We have previously reported a small-scale study that 
found 48％ and 41％ of patients with CH-C and CH-B, respectively, had abnormally high levels 
of RF 3）.  Another group has also reported that RF abnormalities are observed in 4％ of healthy 
subjects12）.  The incidence of abnormal RF levels is reported to be higher in older subjects 
without rheumatic disease, ranging from 3％ to 25％13，14）.  However, our data show that age had 
no affect on high levels of RF in our cohort.
　In the present study, we used the latex turbidimetric assay for determination of RF levels. 
This method is one of the standard methods, licensed in Japan, to determine RF levels.  The 
reference value for RF was less than 7 IU/mL in our assay.  But this reference value has 
been changed to less than 15 IU/mL in Japan recently.  In our previous study, investigating 
abnormalities of LPD markers in patients with CH-C, we regarded patients with an RF of 
more than 10 IU/mL as having a high level3）.  Therefore, in this study we also regarded patients 
with CH-B whose RF was more than 10 IU/mL to have high levels of RF.  The percentage 
of patients with an RF level of more than 15 IU/mL was 34.6％, which was almost the same 
percentage of patients whose RF was more than 10 IU/mL.
　Chronic inflammation of the liver by viruses may play an important role in the production 
of abnormal immunoglobulin, leading to autoimmune diseases and LPDs.  Our former report 
demonstrated that HCV is detected in the B cells of patients with CH-C, and that the presence 
of HCV in B cells was associated with LPDs3）.  There is no report about HBV replication in B 
cells.  The detailed mechanism of immune disorders in patients with CH-B is still unknown.  
　Next we analyzed the factors associated with abnormal levels of RF, but we could not identify 
any host factors on univariate analysis.  Only HBV DNA titers in sera and treatment with 
nucleotide analogues were associated with RF levels.  After antiviral therapy, HBV DNA titers 
and levels of RF were both decreased in patients with CH-B.  Additionally, in patients whose 
HBV DNA was less than 3.0 log copies/mL, only 15.6％ of patients had high levels of RF. 
Figure 2 also directly shows that RF levels reached less than 7 IU/mL when HBV DNA titers 
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became undetectable in two patients with CH-B.  Altogether, these results strongly suggest that 
HBV viremia causes high levels of RF in patients.  Moreover, a difference in HBV genotype is 
not related to the high levels of RF.  This result is consistent with the previous report that HBV 
genotypes are not associated with extrahepatic manifestations10）.  
　The biological significance of high levels of RF in viral hepatitis is hard to explain.  Our 
results do not appear to show any connection between abnormal RF and the presence of B cell 
clonality.  The present study apparently indicates that the link between HBV and immunologic 
disorders and LPDs is weaker than that for HCV.  The difference between these two viruses 
may be related to racial differences.  Further studies are necessary to clarify the molecular 
mechanisms producing the extrahepatic manifestations, LPDs and abnormal levels of RF, and the 
association with malignant lymphoma in patients with viral hepatitis.
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